{
  "schemaVersion": "1.0",
  "exportedAt": "2025-01-15T13:00:00Z",
  "app": "ArguMentor",
  "topics": [
    {
      "id": "850e8400-e29b-41d4-a716-446655440001",
      "title": "Vaccins à ARN messager : Efficacité et sécurité",
      "summary": "Analyse scientifique des vaccins à ARNm, leur efficacité, leurs effets secondaires et les controverses associées",
      "posture": "neutre_critique",
      "tags": ["tag_sante", "tag_science", "tag_vaccins", "tag_covid19"],
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    }
  ],
  "claims": [
    {
      "id": "850e8400-e29b-41d4-a716-446655440101",
      "text": "Les vaccins à ARNm sont sûrs et ne modifient pas l'ADN humain",
      "stance": "pro",
      "strength": "high",
      "topics": ["850e8400-e29b-41d4-a716-446655440001"],
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440102",
      "text": "Les essais cliniques des vaccins ARNm ont été trop courts pour garantir la sécurité à long terme",
      "stance": "con",
      "strength": "medium",
      "topics": ["850e8400-e29b-41d4-a716-446655440001"],
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440103",
      "text": "Les vaccins ARNm ont une efficacité prouvée contre les formes graves de COVID-19",
      "stance": "pro",
      "strength": "high",
      "topics": ["850e8400-e29b-41d4-a716-446655440001"],
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440104",
      "text": "L'efficacité des vaccins ARNm diminue rapidement et nécessite des rappels fréquents",
      "stance": "con",
      "strength": "high",
      "topics": ["850e8400-e29b-41d4-a716-446655440001"],
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440105",
      "text": "Les effets secondaires graves des vaccins ARNm sont extrêmement rares",
      "stance": "pro",
      "strength": "high",
      "topics": ["850e8400-e29b-41d4-a716-446655440001"],
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440106",
      "text": "Les myocardites post-vaccinales chez les jeunes hommes sont sous-estimées et préoccupantes",
      "stance": "con",
      "strength": "medium",
      "topics": ["850e8400-e29b-41d4-a716-446655440001"],
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440107",
      "text": "La vaccination ARNm est justifiée pour toutes les tranches d'âge, y compris les enfants",
      "stance": "pro",
      "strength": "medium",
      "topics": ["850e8400-e29b-41d4-a716-446655440001"],
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440108",
      "text": "Le rapport bénéfice-risque pour les enfants en bonne santé est discutable compte tenu de leur faible risque face au COVID-19",
      "stance": "con",
      "strength": "medium",
      "topics": ["850e8400-e29b-41d4-a716-446655440001"],
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440109",
      "text": "Les vaccins ARNm réduisent significativement la transmission du virus",
      "stance": "pro",
      "strength": "weak",
      "topics": ["850e8400-e29b-41d4-a716-446655440001"],
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440110",
      "text": "Les données montrent que les vaccinés peuvent transmettre le virus presque autant que les non-vaccinés",
      "stance": "con",
      "strength": "high",
      "topics": ["850e8400-e29b-41d4-a716-446655440001"],
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    }
  ],
  "rebuttals": [
    {
      "id": "850e8400-e29b-41d4-a716-446655440201",
      "claimId": "850e8400-e29b-41d4-a716-446655440101",
      "text": "L'ARNm ne peut pas pénétrer dans le noyau cellulaire où se trouve l'ADN, c'est biologiquement impossible sans enzyme de transcription inverse",
      "fallacyTag": "Incompréhension scientifique",
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440202",
      "claimId": "850e8400-e29b-41d4-a716-446655440102",
      "text": "Les essais de phase 3 ont inclus plus de 40 000 participants sur plusieurs mois, et le suivi post-commercialisation a porté sur des milliards de doses",
      "fallacyTag": "Minimisation des données",
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440203",
      "claimId": "850e8400-e29b-41d4-a716-446655440104",
      "text": "La baisse d'efficacité est normale pour tout vaccin contre un virus à mutations rapides, elle ne remet pas en cause la protection contre les formes graves",
      "fallacyTag": "Contexte omis",
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440204",
      "claimId": "850e8400-e29b-41d4-a716-446655440106",
      "text": "Le taux de myocardite post-vaccinale est de 4,8 cas par million de doses chez les 12-29 ans, nettement inférieur au risque de myocardite post-COVID",
      "fallacyTag": "Comparaison de risques manquante",
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440205",
      "claimId": "850e8400-e29b-41d4-a716-446655440109",
      "text": "Les études montrent que l'efficacité contre la transmission diminue à 40-50% après 3 mois pour les variants récents",
      "fallacyTag": "Affirmation obsolète",
      "createdAt": "2025-01-15T13:00:00Z",
      "updatedAt": "2025-01-15T13:00:00Z"
    }
  ],
  "evidences": [
    {
      "id": "850e8400-e29b-41d4-a716-446655440301",
      "claimId": "850e8400-e29b-41d4-a716-446655440101",
      "type": "study",
      "content": "Étude Zhang et al. (Nature, 2021) : 'L'ARNm vaccinal ne peut pas s'intégrer dans l'ADN humain en l'absence de transcriptase inverse'",
      "sourceId": "850e8400-e29b-41d4-a716-446655440401",
      "quality": "high",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440302",
      "claimId": "850e8400-e29b-41d4-a716-446655440103",
      "type": "statistic",
      "content": "Essai Pfizer phase 3 : Efficacité de 95% contre les formes symptomatiques et 100% contre les formes graves (N Engl J Med, 2020)",
      "sourceId": "850e8400-e29b-41d4-a716-446655440402",
      "quality": "high",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440303",
      "claimId": "850e8400-e29b-41d4-a716-446655440104",
      "type": "statistic",
      "content": "Étude israélienne (NEJM, 2021) : L'efficacité du vaccin Pfizer passe de 96% à 84% après 6 mois",
      "sourceId": "850e8400-e29b-41d4-a716-446655440403",
      "quality": "high",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440304",
      "claimId": "850e8400-e29b-41d4-a716-446655440105",
      "type": "statistic",
      "content": "CDC VAERS : Sur 691 millions de doses administrées aux USA (2024), le taux d'effets indésirables graves est de 0,002%",
      "sourceId": "850e8400-e29b-41d4-a716-446655440404",
      "quality": "high",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440305",
      "claimId": "850e8400-e29b-41d4-a716-446655440106",
      "type": "study",
      "content": "Étude de pharmacovigilance française (ANSM, 2022) : Incidence de myocardite de 1 cas pour 20 000 chez les 18-24 ans après la 2e dose de Moderna",
      "sourceId": "850e8400-e29b-41d4-a716-446655440405",
      "quality": "high",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440306",
      "claimId": "850e8400-e29b-41d4-a716-446655440110",
      "type": "study",
      "content": "Étude The Lancet (2022) : La charge virale des personnes vaccinées infectées est similaire à celle des non-vaccinés après l'apparition d'Omicron",
      "sourceId": "850e8400-e29b-41d4-a716-446655440406",
      "quality": "high",
      "createdAt": "2025-01-15T13:00:00Z"
    }
  ],
  "questions": [
    {
      "id": "850e8400-e29b-41d4-a716-446655440501",
      "targetId": "850e8400-e29b-41d4-a716-446655440102",
      "text": "Quel est le délai standard acceptable pour les essais cliniques de vaccins, et pourquoi l'ARNm serait-il différent ?",
      "kind": "clarification",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440502",
      "targetId": "850e8400-e29b-41d4-a716-446655440104",
      "text": "Si l'efficacité diminue après 6 mois, la vaccination de masse est-elle toujours la meilleure stratégie sanitaire ?",
      "kind": "challenge",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440503",
      "targetId": "850e8400-e29b-41d4-a716-446655440108",
      "text": "Comment évaluer objectivement le rapport bénéfice-risque pour des populations à très faible risque de complications du COVID-19 ?",
      "kind": "evidence",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440504",
      "targetId": "850e8400-e29b-41d4-a716-446655440110",
      "text": "Si les vaccinés transmettent le virus, la justification éthique des obligations vaccinales est-elle toujours valable ?",
      "kind": "challenge",
      "createdAt": "2025-01-15T13:00:00Z"
    }
  ],
  "sources": [
    {
      "id": "850e8400-e29b-41d4-a716-446655440401",
      "title": "No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing",
      "citation": "Zhang, L., Richards, A., et al. (2021). Nature Cell Biology, 23(5), 631-639.",
      "url": "https://www.nature.com/articles/s41556-021-00654-y",
      "publisher": "Nature",
      "date": "2021",
      "reliabilityScore": 0.98,
      "notes": "Revue scientifique de référence mondiale",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440402",
      "title": "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine",
      "citation": "Polack, F. P., Thomas, S. J., et al. (2020). N Engl J Med, 383(27), 2603-2615.",
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2034577",
      "publisher": "New England Journal of Medicine",
      "date": "2020",
      "reliabilityScore": 0.99,
      "notes": "Journal médical le plus prestigieux au monde",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440403",
      "title": "Waning Immunity after the BNT162b2 Vaccine in Israel",
      "citation": "Goldberg, Y., Mandel, M., et al. (2021). N Engl J Med, 385(24), e85.",
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2114228",
      "publisher": "New England Journal of Medicine",
      "date": "2021",
      "reliabilityScore": 0.96,
      "notes": "Étude sur données réelles israéliennes",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440404",
      "title": "Vaccine Adverse Event Reporting System (VAERS)",
      "citation": "CDC (2024).",
      "url": "https://vaers.hhs.gov/",
      "publisher": "Centers for Disease Control and Prevention",
      "date": "2024",
      "reliabilityScore": 0.92,
      "notes": "Système de surveillance officiel américain",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440405",
      "title": "Point de situation sur la surveillance des vaccins contre la COVID-19",
      "citation": "ANSM (2022).",
      "url": "https://ansm.sante.fr/dossiers-thematiques/covid-19-vaccins",
      "publisher": "Agence nationale de sécurité du médicament",
      "date": "2022",
      "reliabilityScore": 0.95,
      "notes": "Autorité sanitaire française",
      "createdAt": "2025-01-15T13:00:00Z"
    },
    {
      "id": "850e8400-e29b-41d4-a716-446655440406",
      "title": "Community transmission and viral load kinetics of SARS-CoV-2 in vaccinated and unvaccinated individuals",
      "citation": "Singanayagam, A., Hakki, S., et al. (2022). The Lancet Infectious Diseases, 22(2), 183-195.",
      "url": "https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00648-4/fulltext",
      "publisher": "The Lancet",
      "date": "2022",
      "reliabilityScore": 0.96,
      "notes": "Revue médicale de référence",
      "createdAt": "2025-01-15T13:00:00Z"
    }
  ],
  "tags": [
    {
      "id": "tag_sante",
      "label": "Santé",
      "color": "#F44336"
    },
    {
      "id": "tag_science",
      "label": "Science",
      "color": "#2196F3"
    },
    {
      "id": "tag_vaccins",
      "label": "Vaccins",
      "color": "#009688"
    },
    {
      "id": "tag_covid19",
      "label": "COVID-19",
      "color": "#FF5722"
    }
  ]
}
